OGN: Organon & Co. Stock

by  •  • Comments Off on OGN: Organon & Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,980.54
Enterprise Value ($M) 14,187.54
Book Value ($M) -1,066.00
Book Value / Share -4.19
Price / Book -5.61
NCAV ($M) -7,916.00
NCAV / Share -31.12
Price / NCAV -0.76

Profitability (mra)
Return on Invested Capital (ROIC) 0.11
Return on Assets (ROA) 0.09
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.17
Current Ratio 1.56

Balance Sheet (mrq) ($M)
Current Assets 3,931.00
Assets 10,955.00
Liabilities 11,847.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6,174.00
Operating Income 1,912.00
Net Income 917.00

Cash Flow Statement (mra) ($M)
Cash From Operations 858.00
Cash from Investing -420.00
Cash from Financing -433.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G Mawer Investment Management Ltd. 5.39
02-10 13G State Street Corp 5.06
02-09 13G/A Vanguard Group Inc 12.37 9.37
02-07 13G/A BlackRock Inc. 6.40 -3.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2022-11-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO
2022-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU
2022-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2023-03-31 218,047 1,761,206 12.38
2023-03-30 284,558 1,582,720 17.98
2023-03-29 219,230 1,422,322 15.41
2023-03-28 128,430 1,034,324 12.42
2023-03-27 206,821 1,124,323 18.40

(click for more detail)

Similar Companies
NUVB – Nuvation Bio Inc NVO – Novo-Nordisk A/S
NVS – Novartis AG PBH – Prestige Brands Holdings, Inc.
PFE – Pfizer Inc.


Financial data and stock pages provided by
Fintel.io